CRISPR & Cas Genes Market Regional Analysis:
North America Market Insights
By 2035, North America CRISPR & cas genes market is set to capture over 44.2% revenue share. The region presents a large pool of participants for this sector, attributable to its excellence in genomic alterations, clinical data sharing, and drug discovery. Strategic international collaborations and growing demand in advanced agriculture are also fueling growth in this marketplace. For instance, in May 2024, Pairwise extended its global partnership with Bayer to escalate the reach of its portfolio of CRISPR-based edible goods across North America by upscaling the volume of production and commercialization.
The U.S. is one of the forefront holders of the CRISPR & cas genes market due to its large consumer base and wider channels of applications. The well-established healthcare and biomedical R&D infrastructure of this country is fostering a favorable business environment for global pioneers. In addition, the supportive regulatory framework is playing a crucial role in broadening the adoption range. For instance, in December 2023, the U.S. FDA issued clearance for Casgevy and Lyfgenia for treating sickle cell disease (SCD) in residents aged 12 and older. The approval opened new gateways for novel genome editing technologies and related products, propelling innovation in this merchandise.
Canada is also propagating the CRISPR & cas genes market with government initiatives. With a rapid expansion of the domestic territory of the genome sequencing category, the nation is empowering its emphasis on biomedical advancements and accessibility of therapeutics. On this note, in October 2023, the government of Canada allocated a USD 15.0 million fund for constructing a Pan-Canadian Genome Library. This was intended to make access to genomic data easier for both academia and commercial use. This is evidence of a continuous capital influx in this sector, acting as a financial cushion for future discoveries and analytical excellence, feeding growth in local service providers.
APAC Market Insights
Asia Pacific is predicted to experience the fastest growth pace in the CRISPR & cas genes market during the assessed period. Both agricultural and biomedical demand is fueling this region’s leadership. Rapid emergence in the bioeconomy has positively influenced this merchandise to expand, making it an attractive landscape of trading for global leaders. For instance, in June 2021, Merck’s patent application for its proxy-CRISPR technology was approved by the Japanese Patent Office. This success in authentication widened the reach of the company's genome coverage towards the untapped sections of this country. This indicates the growing interest in foreign forces for greater investments.
India is a large consumer of the agriculture segment in the CRISPR & cas genes market. There is a heavy use of this gene editing tool in improving productivity and quality of farm-based goods. This is also backed by government support, which was highlighted by the PIB press release from November 2022, mentioning a new finding. It stated that a group of scientists at Raman Research Institute (RRI) found a possibility of CRISPR gene-editing in temperature-sensitive organisms, plants, and crops. The scope of development in this country is also signified by its progress in bioeconomy, showcasing a potential to achieve USD 300.0 billion by 2030 (2022 IBEF report).
China is creating new channels of distribution and business opportunities for the CRISPR & cas genes market. In parallel with its neighboring biotech forces, the country is welcoming advanced technologies and MedTech innovations to empower its healthcare and agronomy. For instance, in April 2023, Shandong BellaGen Biotechnology gained a safety certificate for gene-editing in high oleic acid soybeans from the Ministry of Agriculture and Rural Affairs (MOA) in China. This approval initiated the industrial use of this technique on a large scale across the country, inspiring others to affiliate this field with their resourceful participation. Furthermore, China is also proactively incorporating CRISPR-cas9 assets in the medical field.
